AOP ORPHAN FOCUS ON RARE DISEASES
LIVE

Serial Number

79192641

Owner

AOP Orphan Pharmaceuticals AG

Attorney

Michael Fedrick

Filing Date

Jun 2, 2016

Add to watchlist:

No watchlists yet
View on USPTO

AOP ORPHAN FOCUS ON RARE DISEASES Trademark

Serial Number: 79192641 • Registration: 5225397

AOP ORPHAN FOCUS ON RARE DISEASES is a trademark filed by AOP Orphan Pharmaceuticals AG on June 2, 2016. The trademark is classified under Class 5 (Pharmaceuticals), Class 39 (Transportation & Storage), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

AOP Orphan Pharmaceuticals AG (12 trademarks)

Wilhelminenstraße 91/IIf

Entity Type: 99

AOP ORPHAN PHARMACEUTICALS GMBH (16 trademarks)

LEOPOLD-UNGAR-PLATZ 2
VIENNA 1190 , AT

Entity Type: 27

Trademark Details

Filing Date

June 2, 2016

Registration Date

June 20, 2017

Published for Opposition

April 4, 2017

Cancellation Date

January 5, 2024

Goods & Services

Pharmaceutical and medical preparations for the treatment of hematology, oncology, cardiology, neurology, psychiatry, metabolic diseases and genetic disorders; sanitary preparations for medical purposes

Distribution services, namely delivery of medications

Medical advisory and assistance services in the field of medication

Medical and pharmaceutical research and development in the field of hematology, oncology, cardiology, neurology, psychiatry, metabolic diseases and genetic disorders; scientific research and development services in the field of hematology, oncology, cardiology, neurology, psychiatry, metabolic diseases and genetic disorders; industrial research in the field of hematology, oncology, cardiology, neurology, psychiatry, metabolic diseases and genetic disorders; professional consultancy services in the fields of medical and pharmaceutical research and development; contract research services in the field of hematology, oncology, cardiology, neurology, psychiatry, metabolic diseases and genetic disorders; computer programming

Advertising, marketing and promotional consultancy in the field of medication

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Nov 21, 2025 NREP
TOTAL INVALIDATION PROCESSED BY THE IB
Sep 29, 2024 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Sep 11, 2024 INTS
INVALIDATION PROCESSED
Sep 11, 2024 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Sep 6, 2024 INTR
CANCELLED SECTION 71
Jan 5, 2024 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jun 20, 2022 REM3
CHANGE OF NAME/ADDRESS REC'D FROM IB
Dec 18, 2021 ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
Nov 26, 2021 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 28, 2017 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 22, 2017 FICS
FINAL DISPOSITION PROCESSED
Sep 22, 2017 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 20, 2017 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 20, 2017 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 4, 2017 NPUB
PUBLISHED FOR OPPOSITION
Apr 4, 2017 PUBO
NOTIFICATION PROCESSED BY IB
Apr 1, 2017 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 15, 2017 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 15, 2017 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 15, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 28, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 28, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 27, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 27, 2017 TROA
REFUSAL PROCESSED BY IB
Nov 25, 2016 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 4, 2016 RFCS
REFUSAL PROCESSED BY MPU
Nov 4, 2016 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 16, 2016 RFCR
NON-FINAL ACTION WRITTEN
Oct 15, 2016 CNRT
NON-FINAL ACTION WRITTEN
Oct 15, 2016 CNRT
APPLICATION FILING RECEIPT MAILED
Oct 11, 2016 MAFR
ASSIGNED TO EXAMINER
Oct 5, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 5, 2016 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 1, 2016 REPR